Ozempic and Saxenda are two of the most recognized names in GLP-1 weight loss treatment — and they're both injectable, once-weekly-or-daily GLP-1 receptor agonists. But they use entirely different molecules, and that difference matters significantly for how much weight you're likely to lose, how often you inject, what you'll pay, and what your prescriber can legally prescribe for which indication.
This guide compares the two drugs head-to-head: what they are, what the clinical data shows, how the cost stacks up, and who each drug is most appropriate for in 2026.
What They Are: Different Molecules, Same Class
Both drugs belong to the GLP-1 receptor agonist class — they mimic the GLP-1 hormone your gut produces after eating, producing appetite suppression, blood sugar regulation, and slowed gastric emptying. But the similarity largely ends there.
Ozempic contains semaglutide — a GLP-1 analog with a long half-life (~1 week) that enables once-weekly dosing. It's manufactured by Novo Nordisk and FDA-approved for type 2 diabetes management. Its closely related sibling, Wegovy, contains a slightly higher dose of semaglutide (2.4mg vs Ozempic's maximum of 2mg) and is specifically approved for weight management.
Saxenda contains liraglutide — an older GLP-1 analog with a shorter half-life (~13 hours) that requires daily injection. Also manufactured by Novo Nordisk, Saxenda is FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, and in adolescents ages 12 and older.
In terms of potency per receptor interaction, semaglutide is substantially more potent than liraglutide — it binds to GLP-1 receptors more strongly and for longer. This is the primary driver of semaglutide's superior weight loss efficacy.
Efficacy: What the Clinical Trials Show
Saxenda (Liraglutide 3mg): SCALE Trials
The pivotal trials for Saxenda were the SCALE (Satiety and Clinical Adiposeness — Liraglutide Evidence in Non-Diabetic and Diabetic Individuals) program.
SCALE Obesity and Pre-Diabetes (56 weeks, BMI ≥30 or ≥27 with comorbidities, no T2D):
- Mean weight loss of 8.0% at liraglutide 3mg versus 2.6% with placebo
- 63% of patients lost ≥5% body weight (vs 27% placebo)
- 33% lost ≥10% body weight (vs 10% placebo)
SCALE Diabetes (56 weeks, adults with T2D):
- Mean weight loss of 5.0% at liraglutide 3mg versus 2.0% placebo
- Lower efficacy in the presence of T2D, consistent with how the drug class generally performs
These are the numbers that represent Saxenda's ceiling — the maximum dose in an intensive clinical trial setting.
Ozempic/Wegovy (Semaglutide): STEP Trials
The STEP (Semaglutide Treatment Effect in People with Obesity) trials established semaglutide's weight loss profile. The relevant data:
STEP 1 (68 weeks, BMI ≥30 or ≥27 with comorbidities, no T2D, semaglutide 2.4mg/Wegovy dose):
- Mean weight loss of 14.9% versus 2.4% with placebo
- 86% of patients lost ≥5% body weight
- 69% lost ≥10% body weight
- 32% lost ≥20% body weight
STEP 2 (68 weeks, adults with T2D, semaglutide 2.4mg):
- Mean weight loss of 9.6% — lower than STEP 1 but still substantially higher than SCALE Diabetes data for liraglutide
Ozempic at its approved diabetes doses (0.5–2mg): Weight loss is dose-dependent. At 2mg (the highest approved Ozempic dose), weight reduction in clinical practice and trial data falls roughly in the 10–14% range — below the 2.4mg Wegovy dose but substantially above liraglutide.
Direct Comparison
No head-to-head randomized controlled trial has directly compared Ozempic vs Saxenda at their respective maximal doses. But the pooled data tells a consistent story:
| Saxenda (liraglutide 3mg) | Ozempic (semaglutide up to 2mg) | Wegovy (semaglutide 2.4mg) | |
|---|---|---|---|
| Mean weight loss (no T2D) | ~8% | ~10–14% | ~14.9% |
| Mean weight loss (T2D) | ~5% | ~7–10% | ~9.6% |
| ≥5% weight loss | 63% | ~75-80% | 86% |
| ≥10% weight loss | 33% | ~55–65% | 69% |
| ≥20% weight loss | Not commonly achieved | ~20–25% | 32% |
Semaglutide produces meaningfully more weight loss than liraglutide across the board — roughly 1.5–2× the weight reduction at comparable patient populations.
Dosing Schedule: Weekly vs Daily
This is a practical difference that significantly affects treatment experience.
Saxenda: Daily subcutaneous injection. Dose titrated over 5 weeks: 0.6mg → 1.2mg → 1.8mg → 2.4mg → 3.0mg (target dose). Dose escalation takes 5 weeks minimum. Once at 3mg, it's a daily injection indefinitely.
Ozempic: Once-weekly subcutaneous injection. Starting dose 0.25mg/week for 4 weeks, then 0.5mg/week for 4 weeks, escalating to 1.0mg, 2.0mg based on tolerability. The same titration schedule applies.
The daily vs weekly difference matters beyond just convenience. With daily Saxenda, a missed dose is quickly compensated by the next day's injection. With weekly Ozempic, missing a dose creates a full week gap in coverage. The daily injection cycle also means Saxenda patients experience more frequent nausea peaks — though the nausea from each daily dose is generally milder than the post-injection peak from a weekly dose.
For most patients, once-weekly dosing is preferable for adherence. Medication persistence (staying on the drug long-term) correlates strongly with weight loss outcomes — and weekly dosing generally outperforms daily dosing on adherence metrics.
FDA Indications: A Critical Practical Difference
Saxenda is FDA-approved for:
- Chronic weight management in adults with BMI ≥30, or ≥27 with a weight-related condition (hypertension, T2D, dyslipidemia)
- Weight management in adolescents 12 and older with initial BMI at or above the 95th percentile
Ozempic is FDA-approved for:
- Type 2 diabetes — improving glycemic control
- Cardiovascular risk reduction in adults with T2D and established cardiovascular disease
- NOT for weight management (that's Wegovy)
This distinction matters for insurance and for prescribing legality. Prescribers can legally prescribe Ozempic off-label for weight loss — off-label prescribing is legal and common in the US. But insurance plans that cover weight loss medications are likely to cover Saxenda or Wegovy for obesity indications before they cover Ozempic for off-label weight loss.
In practice, Ozempic is widely prescribed for weight loss despite lacking the obesity indication. Many prescribers prefer it for cost, availability, and efficacy reasons.
Cost Without Insurance
Neither drug is inexpensive. Without insurance:
| Saxenda | Ozempic | |
|---|---|---|
| List price (monthly) | ~$1,300–$1,450 | ~$900–$1,100 |
| Manufacturer savings | Novo Nordisk savings card (eligibility varies) | Novo Nordisk savings card (eligibility varies) |
| Generic available? | No | No |
| Compounded version? | Limited — liraglutide is less commonly compounded | Compounded semaglutide widely available ($99–$450/mo) |
The compounded semaglutide market is significantly more developed than compounded liraglutide. Patients who need a lower-cost alternative to brand-name Ozempic have substantially more options than patients who need a lower-cost Saxenda alternative. This cost landscape further tilts the practical choice toward semaglutide.
Side Effects: How They Compare
Both drugs share the same core GLP-1 side effect profile — because they act on the same receptor class.
Most common (both drugs):
- Nausea (most common, affects 20–40% of patients)
- Vomiting
- Diarrhea
- Constipation
- Decreased appetite (partially intended)
Nausea pattern differences:
- Saxenda's daily dosing means nausea peaks more frequently but at lower amplitude — each daily injection produces a smaller nausea spike than a weekly injection
- Ozempic's weekly injection produces a larger nausea spike, but nausea-free days exist between injection peaks
For patients with strong nausea sensitivity, neither is obviously easier — the daily pattern vs weekly spike involves different tolerability profiles, and individual responses vary.
Serious adverse events (both drugs, class-level):
- Thyroid C-cell tumor warning (based on rodent data; relevance in humans is uncertain but merits the class-wide warning)
- Pancreatitis risk (rare)
- Gallbladder disease — cholelithiasis (gallstones) more common with significant weight loss
- Hypoglycemia risk when used with insulin or sulfonylureas
Both drugs share the same contraindications: personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Cardiovascular Data
This is one area where data maturity is relevant.
Semaglutide: The SELECT trial (2023) demonstrated that semaglutide 2.4mg reduced major adverse cardiovascular events (MACE) by 20% in adults with obesity and established cardiovascular disease. This is a significant outcome benefit beyond weight loss. Ozempic's diabetes trials (SUSTAIN-6) also showed cardiovascular benefit.
Liraglutide: The LEADER trial showed liraglutide (at 1.8mg — the diabetes dose, not the Saxenda 3mg dose) reduced MACE by 13% in adults with T2D and high cardiovascular risk. Less data exists at the 3mg obesity dose.
For patients with significant cardiovascular risk, semaglutide's cardiovascular evidence base is more robust and more directly relevant to higher obesity-treatment doses.
Who Should Consider Each Drug
Ozempic is often the better choice when:
- Maximum weight loss efficacy is the priority
- Weekly dosing is preferred for adherence and convenience
- Off-label prescribing for weight loss is acceptable to prescriber and patient
- Compounded semaglutide is a cost-accessible option
- Cardiovascular risk reduction evidence is a consideration
Saxenda may be considered when:
- The obesity FDA indication is important (for insurance coverage of weight management drugs)
- Adolescent weight management is the indication (Saxenda has a pediatric approval; Wegovy also has this in limited contexts, Ozempic does not)
- A prescriber is not willing to prescribe Ozempic off-label for weight management
- Ozempic/semaglutide caused intolerable side effects and a liraglutide alternative is being tried
The honest picture: Saxenda was clinically significant when it launched in 2014, representing the first GLP-1 specifically approved for obesity in the US. Since semaglutide arrived with demonstrably superior efficacy, liraglutide has become a second-line option for most patients. It remains a legitimate treatment choice — particularly for patients who've had issues with semaglutide or who need the specific FDA obesity indication — but the efficacy gap is real.
Looking for a GLP-1 provider that offers semaglutide or can help you navigate the Ozempic vs Saxenda decision? Compare GLP-1 telehealth platforms to see options matched to your location and medication preference.
Clinical data sourced from SCALE Obesity and Pre-Diabetes trial (NEJM 2015), STEP 1 trial (NEJM 2021), LEADER trial (NEJM 2016), and SELECT trial (NEJM 2023). This article is for informational purposes and does not constitute medical advice. Discuss medication choices with a licensed healthcare provider.